MNT3 Antibody

What is the MNT3 Antibody and what biological targets does it recognize?

MNT3 Antibody appears to be related to antibodies targeting either the MAX network transcriptional repressor (MNT) or the muscarinic acetylcholine receptor 3 (mAChR3).

For MNT targets: This protein is also known as ROX, MAD6, MXD6, bHLHd3, max-binding protein MNT, and MAX binding protein. Structurally, the protein is reported to be 62.3 kilodaltons in mass. Anti-MNT antibodies are commercially available with reactivity to human, mouse, and other mammalian orthologs .

For mAChR3 targets: The muscarinic acetylcholine receptor 3 is expressed on cholangiocytes and its signaling is involved in the pathogenesis of chronic inflammatory biliary diseases. Antibodies to mAChR3 have been found in patients with primary biliary cholangitis (PBC) .

What are the primary applications of MNT3 Antibody in research settings?

MNT3 Antibody can be used in multiple research applications depending on its target:

For MNT-targeting antibodies: Common applications include Western Blot (WB), immunohistochemistry on paraffin-embedded tissues (IHC-p), immunocytochemistry (ICC), immunofluorescence (IF), and ELISA .

For mAChR3-targeting antibodies: These are particularly valuable in functional assays measuring receptor inhibition or stimulation, luminometric assays detecting calcium flux, and studies investigating chronic inflammatory biliary diseases .

How should researchers evaluate the quality of MNT3 Antibody before use?

Prior to experimental use, researchers should:

• Verify specificity through multiple validation methods

• Test the antibody in the specific application intended

• Include proper positive and negative controls

• Consider using knockout or knockdown models when available

It has been estimated that approximately 50% of commercial antibodies fail to meet even basic standards for characterization, resulting in significant financial losses and research reliability issues . Therefore, thorough validation is essential before incorporating any antibody into experimental protocols.

How can researchers distinguish between inhibitory and stimulatory antibodies to mAChR3?

Researchers can use functional assays to differentiate between inhibitory and stimulatory antibodies:

Table 1: Classification of Anti-mAChR3 Antibody Activity

The classification is based on luminometric assays measuring changes in intracellular calcium after addition of the mAChR3-agonist carbachol. Results are expressed as percentage of relative luminescence units (RLUs) compared to cells without immunoglobulins .

What methodological approaches exist for designing antibodies with custom specificity profiles?

Advanced computational and experimental approaches can be used to design antibodies with either specific high affinity for particular targets or cross-specificity for multiple targets:

• Identification of different binding modes associated with particular ligands

• Phage display experiments for the selection of antibody libraries against various combinations of ligands

• Computational modeling to disentangle binding modes even when associated with chemically similar ligands

• Optimization of energy functions to generate new sequences:

  • For cross-specific sequences: jointly minimize functions associated with desired ligands

  • For specific sequences: minimize functions for desired ligands while maximizing functions for undesired ligands

This biophysics-informed modeling approach, combined with extensive selection experiments, has broad applicability for designing proteins with desired physical properties .

What is the correlation between anti-mAChR3 antibodies and disease progression in primary biliary cholangitis?

Research has revealed an interesting correlation pattern:

• Inhibitory antibodies to mAChR3 were found in 49-79% of PBC patients, compared to only 26% of controls (p < 0.01)

• Antibody reactivity showed minimal change during disease progression

• No significant correlation was observed with laboratory, clinical, or histological parameters

• Surprisingly, the antibodies were more frequently found in PBC patients with a benign course (96%) than in patients with active disease progressing to late stages within 10 years (57%; p < 0.01)

• Treatment choice (ursodeoxycholic acid, immunosuppressive therapy, or no medication) did not significantly affect antibody reactivity

This suggests that anti-mAChR3 antibodies might serve as potential biomarkers for disease prognosis rather than disease activity.

What is the optimal protocol for detecting functional anti-mAChR3 antibodies?

The luminometric assay is considered the gold standard for detecting functionally active antibodies to mAChR3. The detailed protocol is as follows:

• Cell Preparation:

  • Use either mAChR3-transfected CHO/G5A cells or TFK-1 cells (which constitutively express mAChR3)

  • Seed cells in 96-well plates (12,000 cells/well for TFK-1 cells)

  • Incubate overnight to achieve 80-90% confluence

• Sample Preparation:

  • Prepare ammonium-sulfate precipitated immunoglobulins from sera

  • Dilute to 1:100 (0.15-0.17 mg immunoglobulins/ml)

• Assay Procedure:

  • Pre-incubate cells with Coelenterazine h in HBSS without Ca²⁺

  • Add prepared immunoglobulins to cells for 1 hour

  • Add mAChR3-agonist carbachol (2 μM)

  • Measure change in intracellular calcium during a 20-second integration interval using a luminometer

• Data Analysis:

  • Express results as percentage of relative luminescence units (RLUs) compared to cells without immunoglobulins

  • Classify as stimulation (≥130%) or inhibition (≤70%) based on analyses with healthy controls and ROC curves

How should researchers validate antibody specificity when working with closely related epitopes?

When working with closely related epitopes, researchers should implement a multi-step validation approach:

• Cross-reactivity Testing:

  • Test against a panel of structurally similar proteins

  • Use cells transfected with the target protein versus non-transfected controls

  • Include knockout/knockdown samples when available

• Epitope-specific Validation:

  • Use competing peptides to confirm epitope specificity

  • Apply multiple antibodies targeting different epitopes of the same protein

  • Validate across different experimental conditions

• Computational Approaches:

  • Implement models that can disentangle binding modes associated with similar ligands

  • Use training and test sets to assess computational models

  • Validate predictions experimentally with newly designed antibodies

• Reproducibility Considerations:

  • Document detailed protocols for antibody use

  • Report both positive and negative outcomes from validation tests

  • Consider converting valuable monoclonal antibodies to recombinant formats and making sequences publicly available

What are the best practices for antibody characterization to enhance experimental reproducibility?

To enhance reproducibility when using antibodies like MNT3, researchers should follow these best practices:

• Comprehensive Testing:

  • Screen antibodies in multiple assays beyond simple ELISA

  • Test specifically in the applications where they will be used (WB, IHC, ICC, etc.)

  • Analyze a large number of positives (typically ~90) rather than just a few ELISA-positive clones

• Controls and Validation:

  • Use proper positive controls (expressing the target)

  • Include negative controls (knockout models when possible)

  • Test across multiple experimental conditions and cell types

  • Consider species cross-reactivity when relevant

• Transparency and Documentation:

  • Document detailed protocols

  • Report both positive and negative outcomes of evaluations

  • Make protocols openly available to the scientific community

  • Consider converting valuable monoclonal antibodies to recombinant formats for better reproducibility

• Standardization:

  • Optimize use in each lab and for each specific assay

  • Establish standard operating procedures

  • Use recombinant antibodies when possible to reduce batch-to-batch variability

How can researchers address non-specific binding when using MNT3 Antibody?

When encountering non-specific binding, researchers should:

• Optimize blocking conditions (try different blocking agents: BSA, milk, serum)

• Increase washing stringency (adjust salt concentration, add detergents)

• Titrate antibody concentration to find optimal signal-to-noise ratio

• Pre-adsorb antibody with relevant tissue/cell lysates

• Consider using more specific detection methods or alternative antibodies

What strategies can resolve discrepancies between different antibody-based assays?

When facing contradictory results across different antibody-based methods:

• Carefully review the epitopes recognized by each antibody

• Consider protein conformation differences between assays (native vs. denatured)

• Evaluate potential post-translational modifications affecting epitope accessibility

• Implement orthogonal methods for validation

• Test multiple antibodies targeting different regions of the same protein

How might computational approaches improve MNT3 Antibody design and application?

Computational approaches show significant promise for antibody research:

• Biophysics-informed modeling can predict binding profiles before experimental testing

• Machine learning algorithms can optimize antibody sequences for specific targets

• Computational design can create antibodies with customized cross-reactivity or specificity profiles

• In silico epitope mapping can identify optimal target regions for new antibody development

These approaches may significantly reduce the time and resources needed for antibody development while improving specificity and reducing off-target effects.